EA200500661A1 - Катионный аналог кардиолипина (варианты), его применение (варианты), композиция и набор для трансфекции клеток (варианты) - Google Patents

Катионный аналог кардиолипина (варианты), его применение (варианты), композиция и набор для трансфекции клеток (варианты)

Info

Publication number
EA200500661A1
EA200500661A1 EA200500661A EA200500661A EA200500661A1 EA 200500661 A1 EA200500661 A1 EA 200500661A1 EA 200500661 A EA200500661 A EA 200500661A EA 200500661 A EA200500661 A EA 200500661A EA 200500661 A1 EA200500661 A1 EA 200500661A1
Authority
EA
Eurasian Patent Office
Prior art keywords
options
analogue
cardiolipin
cardiolipine
transfection
Prior art date
Application number
EA200500661A
Other languages
English (en)
Inventor
Могхис У. Ахмад
Кришнуду Касиредди
Имран Ахмад
Original Assignee
Неофарм, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/013917 external-priority patent/WO2004062569A2/en
Priority claimed from PCT/US2003/016412 external-priority patent/WO2003099830A2/en
Application filed by Неофарм, Инк. filed Critical Неофарм, Инк.
Publication of EA200500661A1 publication Critical patent/EA200500661A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Abstract

Представлены катионные соединения-аналоги кардиолипина и способы их синтеза и применения в липосомном препарате для трансфекции генов и т.п. В частности, представлены липосомы, содержащие катионный аналог кардиолипина, фармацевтические композиции, содержащие катионные аналоги кардиолипина, и способы применения данных липосом и композиций для доставки активных фармацевтических агентов при лечении заболеваний человека и животных и/или в диагностических анализах.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500661A 2002-10-16 2003-10-16 Катионный аналог кардиолипина (варианты), его применение (варианты), композиция и набор для трансфекции клеток (варианты) EA200500661A1 (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US41927702P 2002-10-16 2002-10-16
US42928502P 2002-11-26 2002-11-26
US43865903P 2003-01-07 2003-01-07
US46733103P 2003-05-02 2003-05-02
PCT/US2003/013917 WO2004062569A2 (en) 2003-01-07 2003-05-04 Cardiolipin compositions their methods of preparation and use
PCT/US2003/016412 WO2003099830A2 (en) 2002-05-24 2003-05-23 Cardiolipin compositions, methods of preparation and use
PCT/US2003/027806 WO2004039817A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis
PCT/US2003/033099 WO2004035523A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof

Publications (1)

Publication Number Publication Date
EA200500661A1 true EA200500661A1 (ru) 2005-10-27

Family

ID=32234368

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200500659A EA200500659A1 (ru) 2002-10-16 2003-09-05 Способ получения кардиолипина или его аналога (варианты) и содержащей их липосомы, способы использования кардиолипина или его аналогов в лечении болезней (варианты) и содержащая их композиция (варианты) и ее применение
EA200500661A EA200500661A1 (ru) 2002-10-16 2003-10-16 Катионный аналог кардиолипина (варианты), его применение (варианты), композиция и набор для трансфекции клеток (варианты)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200500659A EA200500659A1 (ru) 2002-10-16 2003-09-05 Способ получения кардиолипина или его аналога (варианты) и содержащей их липосомы, способы использования кардиолипина или его аналогов в лечении болезней (варианты) и содержащая их композиция (варианты) и ее применение

Country Status (7)

Country Link
EP (2) EP1556392A1 (ru)
JP (2) JP2006510733A (ru)
AU (2) AU2003268478A1 (ru)
CA (2) CA2502285A1 (ru)
EA (2) EA200500659A1 (ru)
HK (1) HK1080087A1 (ru)
WO (2) WO2004039817A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US20080286351A1 (en) * 2004-06-29 2008-11-20 Ahmad Moghis U Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof
EP1819715A4 (en) * 2004-11-08 2010-02-17 Neopharm Inc SYNTHESIS OF ANALOGOUS PRODUCTS OF CARDIOLIPINE AND THEIR APPLICATIONS
WO2006113679A2 (en) 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
WO2007014150A2 (en) * 2005-07-22 2007-02-01 Neopharm, Inc. Method of administering liposomes containing oligonucleotides
WO2007065017A2 (en) * 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Oligonucleotide cationic liposomal delivery system
US8367628B2 (en) 2005-12-01 2013-02-05 Pronai Therapeutics, Inc. Amphoteric liposome formulation
EP1986607A4 (en) * 2006-02-24 2010-02-10 Neopharm Inc METHOD AND PROCESS FOR THE PRODUCTION OF CARDIOLIPIN
EP2344198B1 (en) * 2008-09-27 2020-11-04 Jina Pharmaceuticals Inc. Lipid based pharmaceutical preparations for topical application
KR101778169B1 (ko) * 2012-04-11 2017-09-13 리폭센 테크놀로지즈 리미티드 미엘린염기성단백질의 올리고펩티드 단편을 함유하는 리포솜, 의약조성물 및 다발성경화증의 치료법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2113606A (en) * 1934-05-24 1938-04-12 Alba Pharmaceutical Company In Quaternary ammonium compounds
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ES2296419T3 (es) * 1998-11-12 2008-04-16 Invitrogen Corporation Reactivos de transfeccion.
ATE283254T1 (de) * 1999-05-28 2004-12-15 Vical Inc Cytofectin-dimere und verfahren zu ihrer anwendung

Also Published As

Publication number Publication date
AU2003268478A1 (en) 2004-05-25
EA200500659A1 (ru) 2005-10-27
JP2006510733A (ja) 2006-03-30
EP1558562A1 (en) 2005-08-03
EP1556392A1 (en) 2005-07-27
AU2003277445A1 (en) 2004-05-04
CA2502285A1 (en) 2004-05-13
WO2004039817A1 (en) 2004-05-13
WO2004035523A1 (en) 2004-04-29
CA2501990A1 (en) 2004-04-29
JP2006503112A (ja) 2006-01-26
WO2004035523B1 (en) 2004-08-26
WO2004039817A9 (en) 2004-07-22
HK1080087A1 (zh) 2006-04-21

Similar Documents

Publication Publication Date Title
SE0200979D0 (sv) New compounds
YU40701A (sh) Piperidini kao modulatori ccr5
ECSP045140A (es) Formulaciones farmacéuticas derivadas del platino
BRPI0406801B8 (pt) derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes
DE60041973D1 (de) Substituierte piperidin-verbindungen als modulatoren der chemokine receptor aktivität
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BRPI0408125A (pt) 1-amino 1h-imidazoquinolinas
ES2179910T3 (es) Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200801243A1 (ru) Фармацевтическое применение замещенных амидов
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
SE9904508D0 (sv) New compounds
ES2156421T3 (es) Composiciones utiles para la transferencia de polinucleotidos terapeuticamente activos a una celula diana y su utilizacion en la terapia genica.
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
SE0100569D0 (sv) New compounds
PT1506185E (pt) Compostos novos e sua utilizacao
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
NO20022599D0 (no) Klorofyll- og bakterioklorofyllesteres, deres fremstilling og farmasöytiske sammensetninger som innbefatter slike
EA200500661A1 (ru) Катионный аналог кардиолипина (варианты), его применение (варианты), композиция и набор для трансфекции клеток (варианты)